Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries

Gauld, Natalie; Bryant, Linda; Emmerton, Lynne; Kelly, Fiona; Kurosawa, Nahoko; Buetow, Stephen

doi:10.1177/1355819615593302

Cited by 25 publications

(55 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The main barrier to reclassification perceived by respondents was opposition from other health professional bodies, which was consistent with pilot interviews and previous Australian research that identified ‘patch protection’ as a barrier to Australian reclassification . This may be influenced by a perceived loss of income as Australian medical practitioners are paid on a fee for service model .…”

Section: Discussionsupporting

confidence: 79%

“…The World Self‐Medication Industry strongly supports international policy change that improves opportunities for self‐care to contribute to improved health outcomes and more sustainable healthcare systems . Perhaps it is time to consider more creative approaches to policy change with regards to medicines reclassification . One creative approach to policy changes is exemplified by New Zealand, where non‐sponsor stakeholders, such as pharmacy retail groups, were proactively involved in reclassification applications within models that balanced increased access with safety controls .…”

Section: Discussionmentioning

confidence: 99%

“…This contrasts with the United States of America (USA) where pharmacy‐only schedules do not exist . A range of other factors have been identified as either enablers or barriers to medicines reclassification . Gauld et al showed that enablers included stakeholders’ confidence in regulators and regulator support .…”

Section: Introductionmentioning

confidence: 99%

“…A range of other factors have been identified as either enablers or barriers to medicines reclassification . Gauld et al showed that enablers included stakeholders’ confidence in regulators and regulator support . Barriers to reclassification included risk averseness, limited trust by regulators in consumers and pharmacists, and ‘patch protection’ by other healthcare professionals, for example the Australian Medical Association has opposed reclassifications .…”

Section: Introductionmentioning

confidence: 99%

“…Barriers to reclassification included risk averseness, limited trust by regulators in consumers and pharmacists, and ‘patch protection’ by other healthcare professionals, for example the Australian Medical Association has opposed reclassifications . These articles identified that Australia had more barriers than enablers when compared with the UK and New Zealand …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Australian pharmacists: ready for increased non-prescription medicines reclassification

Hope

Woods

Mey

et al. 2020

International Journal of Pharmacy Practice

View full text Add to dashboard Cite

Objectives Reclassification of medicines from prescription to non-prescription increases timely access to treatment, promotes self-management of minor ailments and relieves healthcare system burden. Previous research identified that Australia lagged behind the United Kingdom and New Zealand in medicines reclassification. This study aimed to identify Australian pharmacists' opinions on the current state of medicines reclassification; the prescription medicines consumers requested without prescription; the medicines pharmacists believed should and should not be considered for reclassification; and perceived barriers to reclassification. Methods A 2016 national online survey that sought pharmacists' opinions on the state of reclassification, perceived barriers to reclassification and readiness of the profession for further reclassification. Pharmacists' comments were invited through open-ended questions. Key findings Two hundred and thirty-five valid surveys were completed. Respondents practised in community, hospital, consultant and academic contexts, and the majority were female (58.7%, n = 138). More than two thirds (70.66%, n = 166) of pharmacists reported receiving daily or weekly requests for non-prescription access to prescription medicines. The majority of pharmacists (71.7%) agreed that the Australian pharmacy profession is ready for further medicines reclassification, guided by patient safety, harm minimisation and medication continuance. The most prominent barrier to further reclassification was opposition from other healthcare professionals.Conclusions Australian pharmacists believe that their profession has the capacity to safely and effectively manage a wider range of non-prescription medicines through increased reclassification in the contexts of patient safety and risk mitigation. This study has contributed to the global conversation on non-prescription medicines access, providing momentum for practice and policy change.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Australian pharmacists: ready for increased non-prescription medicines reclassification

Hope

Woods

Mey

et al. 2020

International Journal of Pharmacy Practice

View full text Add to dashboard Cite

show abstract

Pediatric Outpatient Prescriptions in Countries With Advanced Economies in the 21st Century

et al. 2022

View full text Add to dashboard Cite

show abstract

A multi user‐centred design approach framework to develop aesthetically pleasing and sustainable OTCP packaging

2023

View full text Add to dashboard Cite

With the healthcare industry moving towards self‐medication, the number of self‐service pharmacies stocking over‐the‐counter pharmaceuticals (OTCP) is rising. The aesthetic attributes of OTCP packaging are critical to attract consumers' attention against competing products. Moreover, sustainable design aims at minimising the negative environmental impacts of packaging. Studies show that stakeholders' interests should be represented more in pharmaceutical packaging, specifically in the early stages of the design process. For this reason, OTCP packaging design is challenging, as sustainable packaging is typically seen as unappealing. Within this context, this paper presents a novel and comprehensive framework aimed at supporting designers to develop aesthetically pleasing and sustainable OTCP packaging, placing multiple users at its core. Studies with OTCP packaging stakeholders were first conducted to identify the framework requirements together with the necessary OTCP packaging attributes. A framework architecture was developed and subsequently implemented in a proof‐of‐concept computer‐based tool. The framework and its implementation were evaluated with the OTCP packaging development stakeholders. Results provide a degree of evidence that the framework contributes significantly to guide OTCP packaging designers in taking the right decisions and can also provide the first steps towards considering aesthetics and sustainability in the packaging design in other sectors, namely, food and beverage.

show abstract

Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries

Cited by 25 publications

References 14 publications

Australian pharmacists: ready for increased non-prescription medicines reclassification

Australian pharmacists: ready for increased non-prescription medicines reclassification

Pediatric Outpatient Prescriptions in Countries With Advanced Economies in the 21st Century

A multi user‐centred design approach framework to develop aesthetically pleasing and sustainable OTCP packaging

Contact Info

Product

Resources

About